

## Special Section on Pediatric Drug Disposition and Pharmacokinetics—Short Communication

# Correlation between Conjugated Bisphenol A Concentrations and Efflux Transporter Expression in Human Fetal Livers<sup>§</sup>

Received November 30, 2015; accepted February 4, 2016

### ABSTRACT

Because of its widespread use in the manufacturing of consumer products over several decades, human exposure to bisphenol A (BPA) has been pervasive. Fetuses are particularly sensitive to BPA exposure, with a number of negative developmental and reproductive outcomes observed in rodent perinatal models. Xenobiotic transporters are one mechanism to extrude conjugated and unconjugated BPA from the liver. In this study, the mRNA expression of xenobiotic transporters and relationships with total, conjugated, and free BPA levels were explored utilizing human fetal liver samples. The mRNA expression of breast cancer resistance protein (BCRP) and multidrug resistance-associated transporter (MRP)4, as well as BCRP and multidrug resistance

transporter 1 exhibited the highest degree of correlation, with  $r^2$  values of 0.941 and 0.816 ( $P < 0.001$  for both), respectively. Increasing concentrations of conjugated BPA significantly correlated with high expression of MRP1 ( $P < 0.001$ ), MRP2 ( $P < 0.05$ ), and MRP3 ( $P < 0.05$ ) transporters, in addition to the NF-E2-related factor 2 transcription factor ( $P < 0.001$ ) and its prototypical target gene, NAD(P)H quinone oxidoreductase 1 ( $P < 0.001$ ). These data demonstrate that xenobiotic transporters may be coordinately expressed in the human fetal liver. This is also the first report of a relationship between environmentally relevant fetal BPA levels and differences in the expression of transporters that can excrete the parent compound and its metabolites.

### Introduction

Bisphenol A (BPA) is an endocrine-disrupting chemical used in the manufacturing of plastics and epoxy resins and is incorporated into a variety of consumer products, including food packaging, children's toys, plastic containers, and medical supplies. There are multiple routes of human exposure to BPA. Leaching of BPA from consumer products has been shown to contaminate food, water, air, and dust (Vandenberg et al., 2007). BPA was investigated for use as a commercial, synthetic estrogen, although it was found to have a significantly weaker potency than diethylstilbestrol (Dodds and Lawson, 1936). Because of widespread use of BPA and its endocrine-disrupting properties, there has been ongoing attention placed on the potential for BPA to negatively affect human health (Ramakrishnan et al., 2009).

Pregnant women and their offspring have been identified as potentially sensitive populations to a number of environmental endocrine-disrupting chemicals, including BPA (reviewed in Rubin, 2011).

This research was supported by the National Institutes of Health Eunice Kennedy Shriver National Institute of Child Health and Human Development [Grant F31HD082965]; the National Institutes of Health National Institute of Environmental Health Sciences [Grants P30ES002022, P30ES017885, R01ES020522, R01ES017524, T32ES007148, and T32ES007062]; and the American Foundation for Pharmaceutical Education [Predoctoral Fellowship in Pharmaceutical Science].

[dx.doi.org/10.1124/dmd.115.068668](http://dx.doi.org/10.1124/dmd.115.068668).

<sup>§</sup>This article has supplemental material available at [dmd.aspetjournals.org](http://dmd.aspetjournals.org).

Biomonitoring studies have detected at least one form of BPA not only in the serum of pregnant women but also in a multitude of reproductive tissues, including cord blood, placenta, and amniotic fluid (Vandenberg et al., 2010), and fetal tissues such as the liver (Zhang et al., 2011; Cao et al., 2012; Nahar et al., 2013). Numerous studies conducted in rodents have associated negative outcomes with in utero exposure to BPA, including alterations to reproductive, neurologic, behavioral, and metabolic development (reviewed in Rubin, 2011). It has been suggested that BPA may interact with multiple hormone and nuclear receptors at low doses, representing one mechanism of action for its endocrine-disrupting activity (Vandenberg et al., 2013). BPA has also been shown to alter the expression of transcription factors in vitro, including pregnane X receptor and NF-E2-related factor 2 (NRF2), although at concentrations higher than those observed with human environmental exposures (Takeshita et al., 2001; Sui et al., 2012; Chepelev et al., 2013).

Because of the relatively low expression of xenobiotic metabolizing enzymes and transporters, fetal livers, across species, have a reduced capacity to deactivate and excrete environmental chemicals (reviewed in Moscovitz and Aleksunes, 2013; Huse et al., 2015). In the human fetal liver, this trend corresponds with nominal expression of basal transcriptional regulators, including the nuclear hormone receptors constitutive androstane receptor and pregnane X receptor (Miki et al., 2005; Pascucci et al., 2007; de Sousa Abreu et al., 2009). Although expression of peroxisome proliferator-activated receptors is comparable between human fetal and adult livers, raw cross threshold (CT) values are high in both groups (Abbott et al., 2010). We have shown that human fetal livers express mRNAs of the phase II detoxifying

**ABBREVIATIONS:** BCRP, breast cancer resistance protein; BPA, bisphenol A; CT, cross threshold; LOQ, limit of quantification; MDR, multidrug resistance transporter; MRP, multidrug resistance-associated transporter; NQO1, NAD(P)H quinone oxidoreductase 1; NRF2, NF-E2-related factor 2; qPCR, quantitative polymerase chain reaction.

enzymes UDP-glucuronosyltransferase 2B15 and sulfotransferase 1A1, albeit at levels lower than adult livers (Nahar et al., 2013). These enzymes are responsible for the conjugation of BPA to glucuronide and sulfate metabolites, respectively, which render the compound inactive (Nishiyama et al., 2002; Hanioka et al., 2008). Interestingly, it has been shown that BPA-glucuronide is transported across the placenta to the rat fetus, where it can be deconjugated and thereby reactivated (Nishikawa et al., 2010). Similarly, it has been shown in sheep that the fetoplacental unit retains conjugated BPA metabolites (Corbel et al., 2013), creating a higher exposure of the fetus to bioactive BPA through conjugation-deconjugation cycling (Corbel et al., 2015; Gauderat et al., 2016). We have demonstrated that human fetal livers exhibit a wide range of quantifiable concentrations of both free and conjugated BPA, whereas levels in adult livers were typically below the limit of quantification (LOQ) (Nahar et al., 2013).

Efflux transporters participate in the excretion of conjugated and unconjugated forms of BPA. BPA-glucuronide is transported in the rat placenta by the multidrug resistance-associated transporter (Mrp)1 and by Mrp2 in the rat liver (Inoue et al., 2005; Nishikawa et al., 2010). An additional report determined that the parent compound can be transported by breast cancer resistance protein (BCRP) in Madin-Darby canine kidney II cells (Dankers et al., 2013). Some studies have suggested differences in substrate specificity between species and that BPA is more likely a substrate for human MRP2 and MRP3, in addition to the BCRP transporter (Mazur et al., 2012). A primary route of efflux has not been determined for BPA and its metabolites in humans; however, in general, MRP1, MRP2, and MRP3 as well as BCRP have a preference for glucuronidated and sulfated compounds (reviewed in Klaassen and Aleksunes, 2010).

Although the ontogeny of human hepatic transporter expression has been described (van Kalken et al., 1992; Chen et al., 2005; Fakhoury et al., 2009; Sharma et al., 2013), modulation of expression in the presence of varying concentrations of BPA as a result of environmental exposures has not been explored. The objective of this study was to investigate relationships between concentrations of unconjugated and conjugated BPA species in human fetal livers and the role of efflux transporter expression in their disposition.

### Materials and Methods

**Tissue Samples.** Human fetal liver samples (gestational days 74–89,  $n = 7$ ; 90–105,  $n = 30$ ; 106–120,  $n = 12$ ; including 26 male and 23 female samples) were obtained from the National Institutes of Health–funded University of Washington Birth Defects Research Laboratory fetal tissue bank (2R24HD000836-47). After consent was obtained, healthy tissue specimens were collected from women undergoing elective pregnancy terminations in the first or second trimester of pregnancy. All human sample collections were carried out in accordance with the Declaration of Helsinki. Samples were immediately flash frozen and stored in polycarbonate-free tubing at  $-80^{\circ}\text{C}$ . Apart from fetal gestational age and sex, no identifying clinical data including race and ethnicity were available. Therefore, samples met the criteria for institutional review board exemption for human subject research (HUM00024929).

**BPA Quantification.** BPA concentrations were determined using high-performance liquid chromatography coupled with API 2000 electrospray triple-quadrupole mass spectrometry by the Kannan Laboratory at the Wadsworth Center (New York State Department of Health, Albany, NY), as previously described (Nahar et al., 2013). Several quality assurance and quality control measurements were taken to ensure the validity of the high-performance liquid chromatography electrospray triple-quadrupole mass spectrometry method. Each time samples were run, sample matrices were spiked with BPA standards (5 ng, internal standard) and passed through the entire analytical procedure. Results indicated an average recovery of 104% (90%–120%) for spiked BPA and

85% (65%–120%) for spiked  $^{13}\text{C}_{12}$ -BPA. An external calibration curve was prepared by injecting standards at varying concentrations (10  $\mu\text{l}$ , 0.05–100 ng/ml), resulting in a calibration coefficient  $> 0.99$ . A procedural blank (water) was included in between every 10 samples analyzed. Concentrations of total, conjugated, and free BPA ranged from below the LOQ at 0.071 ng/g (LOQ/ $\sqrt{2}$ , where LOQ = 0.1 ng/g) to 96.8 ng/g (total), 49.5 ng/g (conjugated), and 50.5 ng/g (free) (Nahar et al., 2013).

**RNA Isolation and Quantitative Polymerase Chain Reaction.** Total RNA was isolated from frozen liver tissue using the AllPrep DNA/RNA/Protein Kit (Qiagen, Valencia, CA) according to the manufacturer's recommendations. Approximately 10–20 mg homogenized tissue was added to 600 ml Buffer RLT with 1%  $\beta$ -mercaptoethanol in a 2-ml round bottom polypropylene tube with a 5-mm stainless steel bead. Samples were further homogenized in solution for 2 minutes at 20 Hz in the TissueLyser II (Qiagen). The concentration and purity of RNA was assessed using the Nanodrop 2000 spectrophotometer (Thermo Scientific, Wilmington, DE). cDNA was generated using High-Capacity cDNA Synthesis (Applied Biosystems, Foster City, CA). mRNA expression was determined by quantitative polymerase chain reaction (qPCR) using the SYBR Green–based method (Applied Biosystems) for detection of amplified products. qPCR primer sequences are listed in (Supplemental Table 1). qPCR was performed in a 384-well plate format using the ViiA7 Real-Time PCR machine (Life Technologies, Grand Island, NY). CT values were converted to  $\Delta\text{CT}$  values by adjusting to a reference gene ( $\beta$ -2-microglobulin) (Livak and Schmittgen, 2001).

**Statistical Analysis.** Data were available for a total of 50 fetal liver samples. Statistical analysis was performed with STATA statistical software (version 14.0; STATA Corp., College Station, TX). A preliminary univariate analysis was carried out for all variables. One outlier subject exhibited a concentration of total BPA more than 4 S.D. above the mean and was excluded from analysis. Correlation matrices for  $r^2$  and  $P$  values were calculated for different species of BPA (total, conjugated, and free) and gestational age and independently for the normalized values of the genes of interest (pwcrr; STATA). Separate linear regression models were computed for each BPA species. The final regression model included the normalized mRNA expression as the independent variable and the concentration of the specific form of BPA as the dependent variable. Statistically significant relationships are shown with  $P < 0.05$ ,  $P < 0.01$ , and  $P < 0.001$ .

### Results and Discussion

Bivariate analysis was conducted using a correlation matrix to examine the association between different species of BPA and gestational age (Table 1). Total BPA and free BPA levels were highly associated, with an  $r^2$  value of 0.963 ( $P < 0.001$ ). The multivariate linear regression model was not significantly affected by the inclusion of gestational age. Thus, this variable was excluded from the final linear regression analyses.

Strength of association was determined for the normalized mRNA expression values of each transporter (Table 2). Evaluation of relationships between transporters in the fetal liver revealed the strongest correlations in mRNA expression between BCRP and MRP4, as well as between BCRP and multidrug transporter (MDR) 1. BCRP and MDR1 both localize to the apical surface of hepatocytes and excrete a variety of substrates into bile. MRP4 is a basolateral

TABLE 1

Correlation matrix for sample characteristics

Summary of the correlations between different BPA species concentrations and gestational age. A value of 1.0 represents a perfect correlation.

Characteristic	Total BPA	Conjugated BPA	Free BPA	Gestational Age
Total BPA	1.00			
Conjugated BPA	0.748*	1.00		
Free BPA	0.963*	0.539*	1.00	
Gestational age	0.199	0.067	0.224	1.00

\* $P < 0.001$ .

TABLE 2

Normalized gene expression correlation matrix

Summary of the correlations between gene expression of different transcription factors and transporters in human fetal liver. A value of 1.0 represents a perfect correlation.

Gene	MRP1	MRP2	MRP3	MRP4	MDR1	BCRP	NRF2	NQO1
MRP1	1.00							
MRP2	0.739*	1.00						
MRP3	0.462*	0.301***	1.00					
MRP4	0.380**	0.169	0.741*	1.00				
MDR1	0.320***	0.147	0.689*	0.734*	1.00			
BCRP	0.370**	0.212	0.796*	0.941*	0.816*	1.00		
NRF2	0.418**	0.235	0.315***	0.266	0.266	0.264	1.00	
NQO1	0.859*	0.597*	0.300***	0.302***	0.167	0.233	0.475*	1.00

\* $P < 0.001$ ; \*\* $P < 0.01$ ; \*\*\* $P < 0.05$ .

efflux transporter and is known to pump sulfated conjugates back into the blood. In fact, BCRP and MRP4 have significant overlap in preference for sulfated substrates (Suzuki et al., 2003; Zelcer et al., 2003). It has been demonstrated that these two transporters can work in concert to efflux purine analogs from the livers of mice (Takenaka et al., 2007). Similarly, the cooperation between Mdr1 and Bcrp (and to a lesser extent, Mrp4) has been noted in mice at the blood-brain and blood-testis barriers (Kodaira et al., 2010).

Strength of association between normalized mRNA levels and BPA was computed by simple linear regression analysis (Table 3). Increasing concentrations of conjugated BPA in fetal livers, but not total or free BPA levels, were significantly associated with elevated expression of NRF2, NAD(P)H quinone oxidoreductase 1 (NQO1), and MRP1 mRNAs, as well as MRP2 and MRP3 mRNAs ( $P < 0.05$ ). For the three genes (NRF2, NQO1, and MRP1) that were highly associated with conjugated BPA ( $P < 0.001$ ), the observed data points, the regression line and the 95% confidence intervals were plotted (Fig. 1). Upregulation of transporters in the presence of increasing conjugated BPA levels may reflect an adaptation to enhance excretion of the parent compound and its conjugates from the fetal liver. Likewise, NRF2 has been shown to induce gene expression of MRP2 and MRP3 in human primary hepatocytes and human hepatoma HepG2 cells (Jigorel et al., 2006; Adachi et al., 2007). Interestingly, in the same study, MRP1 mRNA expression was enhanced with treatment of an NRF2 agonist, *tert*-butylhydroquinone; however, its elevated expression was not attenuated by transfection with NRF2 small interfering RNA (Adachi et al., 2007). In this study, a strong relationship between NQO1 and MRP1 gene expression was revealed ( $r^2 = 0.859$ ; Table 2). Thus, although MRP1 expression may not depend on NRF2 activation, it could be induced by the presence of similar xenobiotics.

The human fetal liver is the main site of hematopoiesis from gestation days 60 to 195. This activity precedes metabolic functions the liver acquires later in development, when primary hematopoiesis shifts to the bone marrow. Thus, the structure of the fetal liver is more loosely defined than the complex liver lobules of the adult. In addition, immunohistochemical staining showed expression of sulfotransferase 1A1 protein in not only hepatocytes but also hematopoietic cells of the developing liver (Richard et al., 2001). It is essential to note that although both MRP1 and MRP4 are lowly expressed in the human adult liver (Hilgendorf et al., 2007), data from this study indicate that their raw CT values are comparable to those of other highly enriched transporters such as MRP3 and BCRP in the human fetal liver. Importantly, the presence of hematopoietic progenitors, not just hepatocytes, as well as the ontogenic expression of transporters may contribute to the altered response of the fetal liver to xenobiotics such as BPA.

Because of the limited availability of samples, many ontogenic studies, particularly in humans, rely on mRNA levels to evaluate fetal expression patterns for metabolic enzymes and transporters. Studies have shown that mRNA abundance can explain up to 40% of variance in protein expression in humans, although it still cannot account for translational modifications and protein degradation that contribute to the ultimate presence of a protein in a tissue (de Sousa Abreu et al., 2009; Ramakrishnan et al., 2009). Future analysis would benefit from the quantification of efflux transporter proteins and BPA metabolites by liquid chromatography/mass spectrometry in addition to mRNA profiling.

Although conjugated species were differentiated from total and free BPA in these samples, the type of conjugation was not identified. As previously mentioned, although many of these transporters show preference for sulfated conjugates, they are also capable of transporting


TABLE 3

Regression coefficients for gene expression and BPA levels in human fetal livers

Regression coefficients ( $\beta$ ) were calculated from simple linear regression analysis for each gene and BPA species ( $n = 49$ ).

Gene	BPA Species					
	Total		Conjugated		Free	
	$\beta$	$P$ Value	$\beta$	$P$ Value	$\beta$	$P$ Value
MRP1	$1.45 \times 10^{-3}$	0.666	$1.13 \times 10^{-2}$	<0.001*	$4.36 \times 10^{-4}$	0.728
MRP2	$3.79 \times 10^{-4}$	0.815	$5.54 \times 10^{-3}$	0.038**	$-3.14 \times 10^{-4}$	0.779
MRP3	$8.82 \times 10^{-4}$	0.350	$7.12 \times 10^{-3}$	0.013**	$2.26 \times 10^{-4}$	0.851
MRP4	$1.19 \times 10^{-3}$	0.185	$4.79 \times 10^{-3}$	0.085	$1.11 \times 10^{-3}$	0.332
MDR1	$5.16 \times 10^{-4}$	0.677	$3.37 \times 10^{-3}$	0.380	$2.62 \times 10^{-4}$	0.868
BCRP	$1.03 \times 10^{-3}$	0.288	$4.45 \times 10^{-3}$	0.138	$9.08 \times 10^{-4}$	0.462
NRF2	$1.82 \times 10^{-3}$	0.057	$1.04 \times 10^{-2}$	<0.001*	$1.19 \times 10^{-3}$	0.334
NQO1	$1.66 \times 10^{-3}$	0.124	$1.27 \times 10^{-2}$	<0.001*	$1.19 \times 10^{-3}$	0.334

\* $P < 0.001$ ; \*\* $P < 0.05$ .



**Fig. 1.** Univariate modeling of gene expression and conjugated BPA levels in fetal livers. Linear regressions for NRF2 mRNA, NQO1 mRNA, MRP1 mRNA, and conjugated BPA levels are shown. Data are presented as mean relative expression ( $n = 49$ , normalized to  $\beta$ -2-microglobulin). Dashed lines represent 95% confidence limits. B2M,  $\beta$ -2-microglobulin.

the glucuronidated and parent forms. Therefore, the unique influence of each type of conjugation pathway on xenobiotic transporter expression in fetal livers cannot be determined. However, studies in sheep have demonstrated that maternal intravenous administration of BPA results in a substantial presence of BPA-glucuronide in the fetus (Gauderat et al., 2016), and to a greater extent than BPA-sulfate (Corbel et al., 2013, 2015). The authors also showed that microsomes and cytosols prepared from both fetal ewe and human livers have similar activity toward BPA glucuronidation and sulfation, respectively (Corbel et al., 2015). Taken together, it is possible that BPA-glucuronide represents a greater fraction of the conjugated BPA in the human fetal livers from this study.

This is the first report of an association between BPA species at environmentally relevant exposure levels and differences in mRNA expression of xenobiotic transporters in fetal livers. Furthermore, activation of NRF2 in these samples was indicated by upregulation of its prototypical target gene NQO1. Because many other transcription factors are lowly expressed in the human fetal liver, NRF2 should be explored as a candidate transcription factor responsible for BPA-mediated transporter induction. Using a novel type of analysis in human fetal samples, this study suggests that expression of important excretory pathways in fetal livers may be altered when exposed to xenobiotics in utero.

#### Acknowledgments

The authors thank the University of Washington Birth Defects Research Laboratory (R24HD000836-47) for human tissue sample collection. The authors also thank Dr. Kurunthachalam Kannan and Dr. Chunyang Liao from the Wadsworth Center for BPA analysis in fetal tissue.

Department of Pharmacology and Toxicology, Ernest Mario School of Pharmacy, Rutgers University, Piscataway, New Jersey (J.E.M., L.M.A.); Department of Environmental Health Sciences, University of Michigan, Ann Arbor, Michigan (M.S.N., D.C.D.); Division of Environmental Health, School of Public Health, Georgia State University, Atlanta, Georgia (S.L.S.); Robert Wood Johnson Medical School, Rutgers University, Piscataway, New Jersey (S.L.S.); Environmental and Occupational Health Sciences Institute, Piscataway, New Jersey (S.L.S., L.M.A.); Department of Biomedical and Pharmaceutical Sciences, University of Rhode Island, Kingston, Rhode Island (A.L.S.); and Department of Nutritional Sciences, University of Michigan, Ann Arbor, Michigan (D.C.D.)

JAMIE E. MOSCOVITZ  
MUNA S. NAHAR  
STUART L. SHALAT  
ANGELA L. SLITT  
DANA C. DOLINOY  
LAUREN M. ALEKSUNES

#### Authorship Contributions

Participated in research design: Moscovitz, Nahar, Slitt, Dolinoy, Aleksunes.  
Conducted experiments: Moscovitz, Nahar.  
Contributed new reagents or analytic tools: Shalat, Dolinoy.  
Performed data analysis: Moscovitz, Shalat, Aleksunes.  
Wrote or contributed to the writing of the manuscript: Moscovitz, Nahar, Shalat, Slitt, Dolinoy, Aleksunes.

#### References

- Abbott BD, Wood CR, Watkins AM, Das KP, and Lau CS (2010) Peroxisome proliferator-activated receptors alpha, beta, and gamma mRNA and protein expression in human fetal tissues. *PPAR Res* **2010**:690907.
- Adachi T, Nakagawa H, Chung I, Hagiya Y, Hoshijima K, Noguchi N, Kuo MT, and Ishikawa T (2007) Nrf2-dependent and -independent induction of ABC transporters ABCC1, ABCC2, and ABCG2 in HepG2 cells under oxidative stress. *J Exp Ther Oncol* **6**:335–348.
- Cao XL, Zhang J, Goodyer CG, Hayward S, Cooke GM, and Curran IH (2012) Bisphenol A in human placental and fetal liver tissues collected from Greater Montreal area (Quebec) during 1998–2008. *Chemosphere* **89**:505–511.
- Chen HL, Chen HL, Liu YJ, Feng CH, Wu CY, Shyu MK, Yuan RH, and Chang MH (2005) Developmental expression of canalicular transporter genes in human liver. *J Hepatol* **43**:472–477.
- Chepelev NL, Enikanolaiye MI, Chepelev LL, Almohaisen A, Chen Q, Scoggan KA, Coughlan MC, Cao XL, Jin X, and Willmore WG (2013) Bisphenol A activates the Nrf1/2-antioxidant response element pathway in HEK 293 cells. *Chem Res Toxicol* **26**:498–506.
- Corbel T, Gayrard V, Viguié C, Puel S, Lacroix MZ, Toutain PL, and Picard-Hagen N (2013) Bisphenol A disposition in the sheep maternal-placental-fetal unit: mechanisms determining fetal internal exposure. *Biol Reprod* **89**:11.
- Corbel T, Perdu E, Gayrard V, Puel S, Lacroix MZ, Viguié C, Toutain PL, Zalko D, and Picard-Hagen N (2015) Conjugation and deconjugation reactions within the fetoplacental compartment in a sheep model: a key factor determining bisphenol A fetal exposure. *Drug Metab Dispos* **43**:467–476.
- Dankers AC, Roelofs MJ, Piersma AH, Sweep FC, Russel FG, van den Berg M, van Duursen MB, and Masereeuw R (2013) Endocrine disruptors differentially target ATP-binding cassette transporters in the blood-testis barrier and affect Leydig cell testosterone secretion in vitro. *Toxicol Sci* **136**:382–391.
- de Sousa Abreu R, Penalva LO, Marcotte EM, and Vogel C (2009) Global signatures of protein and mRNA expression levels. *Mol Biosyst* **5**:1512–1526.
- Dodds EC and Lawson W (1936) Synthetic oestrogenic agents without the phenanthrene nucleus. *Nature* **137**:996.
- Fakhoury M, de Beaumais T, Guimiot F, Azougagh S, Elie V, Medard Y, Delezoide AL, and Jacqz-Aigrain E (2009) mRNA expression of MDR1 and major metabolizing enzymes in human fetal tissues. *Drug Metab Pharmacokin* **24**:529–536.
- Gauderat G, Picard-Hagen N, Toutain PL, Corbel T, Viguié C, Puel S, Lacroix MZ, Mindeguia P, Bousquet-Melou A, and Gayrard V (2016) Bisphenol A glucuronide deconjugation is a determining factor of fetal exposure to bisphenol A. *Environ Int* **86**:52–59.
- Hanioka N, Naito T, and Narimatsu S (2008) Human UDP-glucuronosyltransferase isoforms involved in bisphenol A glucuronidation. *Chemosphere* **74**:33–36.
- Hilgendorf C, Ahlin G, Seithel A, Artursson P, Ungell AL, and Karlsson J (2007) Expression of thirty-six drug transporter genes in human intestine, liver, kidney, and organotypic cell lines. *Drug Metab Dispos* **35**:1333–1340.

- Huse SM, Gruppiso PA, Boekelheide K, and Sanders JA (2015) Patterns of gene expression and DNA methylation in human fetal and adult liver. *BMC Genomics* **16**:981.
- Inoue H, Tsuruta A, Kudo S, Ishii T, Fukushima Y, Iwano H, Yokota H, and Kato S (2005) Bisphenol A glucuronidation and excretion in liver of pregnant and nonpregnant female rats. *Drug Metab Dispos* **33**:55–59.
- Jigorel E, Le Vee M, Boursier-Neyret C, Parmentier Y, and Fardel O (2006) Differential regulation of sinusoidal and canalicular hepatic drug transporter expression by xenobiotics activating drug-sensing receptors in primary human hepatocytes. *Drug Metab Dispos* **34**:1756–1763.
- Klaassen CD and Aleksunes LM (2010) Xenobiotic, bile acid, and cholesterol transporters: function and regulation. *Pharmacol Rev* **62**:1–96.
- Kodaira H, Kusahara H, Ushiki J, Fuse E, and Sugiyama Y (2010) Kinetic analysis of the cooperation of P-glycoprotein (P-gp/Abcb1) and breast cancer resistance protein (Bcrp/Abcg2) in limiting the brain and testis penetration of erlotinib, flavopiridol, and mitoxantrone. *J Pharmacol Exp Ther* **333**:788–796.
- Livak KJ and Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(-delta delta C(T)) method. *Methods* **25**:402–408.
- Mazur CS, Marchitti SA, Dimova M, Kenneke JF, Lumen A, and Fisher J (2012) Human and rat ABC transporter efflux of bisphenol A and bisphenol A glucuronide: interspecies comparison and implications for pharmacokinetic assessment. *Toxicol Sci* **128**:317–325.
- Miki Y, Suzuki T, Tazawa C, Blumberg B, and Sasano H (2005) Steroid and xenobiotic receptor (SXR), cytochrome P450 3A4 and multidrug resistance gene 1 in human adult and fetal tissues. *Mol Cell Endocrinol* **231**:75–85.
- Moscovitz JE and Aleksunes LM (2013) Establishment of metabolism and transport pathways in the rodent and human fetal liver. *Int J Mol Sci* **14**:23801–23827.
- Nahar MS, Liao C, Kannan K, and Dolinoy DC (2013) Fetal liver bisphenol A concentrations and biotransformation gene expression reveal variable exposure and altered capacity for metabolism in humans. *J Biochem Mol Toxicol* **27**:116–123.
- Nishikawa M, Iwano H, Yanagisawa R, Koike N, Inoue H, and Yokota H (2010) Placental transfer of conjugated bisphenol A and subsequent reactivation in the rat fetus. *Environ Health Perspect* **118**:1196–1203.
- Nishiyama T, Ogura K, Nakano H, Kaku T, Takahashi E, Ohkubo Y, Sekine K, Hiratsuka A, Kadota S, and Watabe T (2002) Sulfation of environmental estrogens by cytosolic human sulfotransferases. *Drug Metab Pharmacokinet* **17**:221–228.
- Pascucci JM, Robert A, Moreau A, Ramos J, Bioulac-Sage P, Navarro F, Blanc P, Assenat E, Maurel P, and Vilarem MJ (2007) Differential regulation of constitutive androstane receptor expression by hepatocyte nuclear factor4alpha isoforms. *Hepatology* **45**:1146–1153.
- Ramakrishnan SR, Vogel C, Prince JT, Li Z, Penalva LO, Myers M, Marcotte EM, Miranker DP, and Wang R (2009) Integrating shotgun proteomics and mRNA expression data to improve protein identification. *Bioinformatics* **25**:1397–1403.
- Richard K, Hume R, Kaptein E, Stanley EL, Visser TJ, and Coughtrie MW (2001) Sulfation of thyroid hormone and dopamine during human development: ontogeny of phenol sulfotransferases and arylsulfatase in liver, lung, and brain. *J Clin Endocrinol Metab* **86**:2734–2742.
- Rubin BS (2011) Bisphenol A: an endocrine disruptor with widespread exposure and multiple effects. *J Steroid Biochem Mol Biol* **127**:27–34.
- Sharma S, Ellis EC, Gramignoli R, Dorko K, Tahan V, Hansel M, Mattison DR, Caritis SN, Hines RN, and Venkataraman R, et al. (2013) Hepatobiliary disposition of 17-OHPC and taurocholate in fetal human hepatocytes: a comparison with adult human hepatocytes. *Drug Metab Dispos* **41**:296–304.
- Sui Y, Ai N, Park SH, Rios-Pilier J, Perkins JT, Welsh WJ, and Zhou C (2012) Bisphenol A and its analogues activate human pregnane X receptor. *Environ Health Perspect* **120**:399–405.
- Suzuki M, Suzuki H, Sugimoto Y, and Sugiyama Y (2003) ABCG2 transports sulfated conjugates of steroids and xenobiotics. *J Biol Chem* **278**:22644–22649.
- Takenaka K, Morgan JA, Scheffer GL, Adachi M, Stewart CF, Sun D, Legg M, Ejendal KF, Hrycyna CA, and Schuetz JD (2007) Substrate overlap between Mrp4 and Abcg2/Bcrp affects purine analogue drug cytotoxicity and tissue distribution. *Cancer Res* **67**:6965–6972.
- Takeshita A, Koibuchi N, Oka J, Taguchi M, Shishiba Y, and Ozawa Y (2001) Bisphenol-A, an environmental estrogen, activates the human orphan nuclear receptor, steroid and xenobiotic receptor-mediated transcription. *Eur J Endocrinol* **145**:513–517.
- Vandenberg LN, Chahoud I, Heindel JJ, Padmanabhan V, Paumgarten FJ, and Schoenfelder G (2010) Urinary, circulating, and tissue biomonitoring studies indicate widespread exposure to bisphenol A. *Environ Health Perspect* **118**:1055–1070.
- Vandenberg LN, Ehrlich S, Belcher SM, Ben-Jonathan N, Dolinoy DC, Hugo ER, Hunt PA, Newbold RR, Rubin BS, and Sali KS, et al. (2013) Low dose effects of bisphenol A. *Endocr Disruptors (Austin)* **1**:e26490.
- Vandenberg LN, Hauser R, Marcus M, Olea N, and Welshons WV (2007) Human exposure to bisphenol A (BPA). *Reprod Toxicol* **24**:139–177.
- van Kalken CK, Giaccone G, van der Valk P, Kuiper CM, Hadisaputro MM, Bosma SA, Scheper RJ, Meijer CJ, and Pinedo HM (1992) Multidrug resistance gene (P-glycoprotein) expression in the human fetus. *Am J Pathol* **141**:1063–1072.
- Zelcer N, Reid G, Wielinga P, Kuil A, van der Heijden I, Schuetz JD, and Borst P (2003) Steroid and bile acid conjugates are substrates of human multidrug-resistance protein (MRP) 4 (ATP-binding cassette C4). *Biochem J* **371**:361–367.
- Zhang J, Cooke GM, Curran IH, Goodyer CG, and Cao XL (2011) GC-MS analysis of bisphenol A in human placental and fetal liver samples. *J Chromatogr B Anal Technol Biomed Life Sci* **879**:209–214.

---

**Address correspondence to:** Lauren M. Aleksunes, Department of Pharmacology and Toxicology, Ernest Mario School of Pharmacy, Rutgers University, 170 Frelinghuysen Road, Piscataway, NJ 08854. E-mail: aleksunes@eohsi.rutgers.edu

---